Literature DB >> 31101421

Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.

Eun-Ju Ko1, Youri Lee2, Young-Tae Lee2, Yu-Jin Jung3, Vu L Ngo4, Min-Chul Kim5, Ki-Hye Kim2, Bao-Zhong Wang6, Andrew T Gewirtz7, Sang-Moo Kang8.   

Abstract

Incorporation of membrane-anchored flagellin molecules into the surfaces of influenza virus-like particles (VLP) was previously reported to promote T helper (Th) 1-biased IgG antibody production and protective efficacy of co-presented vaccine antigens. Herein, we investigated the potential adjuvant effects and mechanisms of flagellin-expressing VLP (FliC-VLP) as an independent component on influenza vaccination in wild-type and mutant mouse models. FliC-VLP adjuvanted influenza vaccination was highly effective in promoting the induction of Th1-biased IgG isotype switched antibodies, enhanced protection, and long-lasting IgG antibody responses in both wild-type and CD4-knockout mice. In contrast, the adjuvant effects of soluble flagellin were Th2-biased and required CD4 T helper cells. The adjuvant effects of FliC-VLP were less dependent on CD4 T cells and flagellin-mediated innate immune signaling pathways. The results suggest that FliC-VLP might play an effective adjuvant role in an immune competent condition as well as in a defect of CD4 T cells.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; CD4 T cells; Flagellin; Influenza; VLP

Year:  2019        PMID: 31101421      PMCID: PMC7274143          DOI: 10.1016/j.vaccine.2019.05.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  44 in total

1.  Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo.

Authors:  Stephen J McSorley; Benjamin D Ehst; Yimin Yu; Andrew T Gewirtz
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

2.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Authors:  Grazia Galli; Duccio Medini; Erica Borgogni; Luisanna Zedda; Monia Bardelli; Carmine Malzone; Sandra Nuti; Simona Tavarini; Chiara Sammicheli; Anne K Hilbert; Volker Brauer; Angelika Banzhoff; Rino Rappuoli; Giuseppe Del Giudice; Flora Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 3.  Flagellin as an adjuvant: cellular mechanisms and potential.

Authors:  Steven B Mizel; John T Bates
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

4.  Humoral immune response to flagellin requires T cells and activation of innate immunity.

Authors:  Catherine J Sanders; Yimin Yu; Daniel A Moore; Ifor R Williams; Andrew T Gewirtz
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 5.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

6.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

8.  Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.

Authors:  Yu-Jin Kim; Young-Tae Lee; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Eun-Ju Ko; Jae-Min Song; Sang-Moo Kang
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

9.  Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

Authors:  Constantino López-Macías; Eduardo Ferat-Osorio; Alejandra Tenorio-Calvo; Armando Isibasi; Juan Talavera; Oscar Arteaga-Ruiz; Lourdes Arriaga-Pizano; Somia P Hickman; María Allende; Kathy Lenhard; Steven Pincus; Kevin Connolly; Ramadevi Raghunandan; Gale Smith; Gregory Glenn
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

10.  The CD8 population in CD4-deficient mice is heavily contaminated with MHC class II-restricted T cells.

Authors:  Aaron J Tyznik; Joseph C Sun; Michael J Bevan
Journal:  J Exp Med       Date:  2004-02-09       Impact factor: 14.307

View more
  3 in total

Review 1.  Inflammasomes and adaptive immune responses.

Authors:  Katherine A Deets; Russell E Vance
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

2.  Improving immunogenicity and safety of flagellin as vaccine carrier by high-density display on virus-like particle surface.

Authors:  Yiwen Zhao; Zhuofan Li; Xiaoyue Zhu; Yan Cao; Xinyuan Chen
Journal:  Biomaterials       Date:  2020-04-12       Impact factor: 12.479

3.  Progress in the development of virus-like particle vaccines against respiratory viruses.

Authors:  Fu-Shi Quan; Swarnendu Basak; Ki-Back Chu; Sung Soo Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2020-01-18       Impact factor: 5.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.